AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 8618789 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin (3 x 0.2 mg/kg/12 h)
Number of subjects: 75
Study 8618789 — intervention group
Group type: COMPARATOR
Intervention: Aspirin (4 x 15 mg/kg/6 h)
Number of subjects: 75
Study 8618789 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin
Number of subjects: 75
Study 2744182 — intervention group
Group type: EXPERIMENTAL
Intervention: Embryo transfer at 44 to 48 hours after insemination
Number of subjects: 51
Study 2744182 — intervention group
Group type: EXPERIMENTAL
Intervention: Embryo transfer at 68 to 72 hours after insemination
Number of subjects: 51
Study 2744182 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential embryo transfer at 44 to 48 and 68 to 72 hours after insemination
Number of subjects: 51
Study 952335 — intervention group
Group type: EXPERIMENTAL
Intervention: Outpatient group
Number of subjects: 0
Study 952335 — intervention group
Group type: COMPARATOR
Intervention: Inpatient group
Number of subjects: 0
Study 31397551 — intervention group
Group type: EXPERIMENTAL
Intervention: Active attentional bias modification (ABM) training for 14 days
Number of subjects: 134
Study 31397551 — intervention group
Group type: COMPARATOR
Intervention: Placebo training for 14 days
Number of subjects: 134
Study 31397551 — intervention group
Group type: EXPERIMENTAL
Intervention: Active attentional bias modification (ABM) training
Number of subjects: 134
Study 30427231 — intervention group
Group type: EXPERIMENTAL
Intervention: PTPD‐12 moisturizer
Number of subjects: 43
Study 30427231 — intervention group
Group type: COMPARATOR
Intervention: Control moisturizer
Number of subjects: 43
Study 28561184 — intervention group
Group type: EXPERIMENTAL
Intervention: Isocaloric diet (diet group, n=6)
Number of subjects: 12
Study 28561184 — intervention group
Group type: COMPARATOR
Intervention: Regular unrestricted diet (non‐diet group, n=6)
Number of subjects: 12
Study 24602919 — intervention group
Group type: EXPERIMENTAL
Intervention: Left coronary dominance
Number of subjects: 1387
Study 24602919 — intervention group
Group type: COMPARATOR
Intervention: Non-left dominance
Number of subjects: 1387
Study 23403680 — intervention group
Group type: EXPERIMENTAL
Intervention: Tedizolid phosphate (200 mg once daily for 6 days)
Number of subjects: 667
Study 23403680 — intervention group
Group type: COMPARATOR
Intervention: Linezolid (600 mg every 12 hours for 10 days)
Number of subjects: 667
Study 21702678 — intervention group
Group type: EXPERIMENTAL
Intervention: Resin-modified glass ionomer liner
Number of subjects: 48
Study 21702678 — intervention group
Group type: COMPARATOR
Intervention: Flowable resin composite liners
Number of subjects: 48
Study 21702678 — intervention group
Group type: COMPARATOR
Intervention: Two kinds of adhesive systems (Single Bond and Clearfil SE Bond)
Number of subjects: 48
Study 20184056 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical diltiazem hydrochloride ointment (2%)
Number of subjects: 102
Study 20184056 — intervention group
Group type: COMPARATOR
Intervention: Topical glyceryl trinitrate ointment (0.2%)
Number of subjects: 102
Study 16702331 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin A supplementation among HIV-1 infected participants
Number of subjects: 600
Study 16702331 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV-1 infection
Number of subjects: 600
Study 16702331 — intervention group
Group type: COMPARATOR
Intervention: RBP:TTR cut-off value of 0.25
Number of subjects: 600
Study 16702331 — intervention group
Group type: COMPARATOR
Intervention: Acute phase response
Number of subjects: 600
Study 15651756 — intervention group
Group type: EXPERIMENTAL
Intervention: Twice-daily indinavir/ritonavir (800/100 mg) regimen
Number of subjects: 118
Study 15651756 — intervention group
Group type: COMPARATOR
Intervention: Three-times-daily indinavir regimen
Number of subjects: 118
Study 11234265 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol (25 mg)
Number of subjects: 71
Study 11234265 — intervention group
Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate
Number of subjects: 71
Study 11234265 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 71
Study 9413804 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium valproate (SV) 400 mg
Number of subjects: 33
Study 9413804 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium valproate (SV) 800 mg
Number of subjects: 33
Study 9413804 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study 8549956 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic inspiratory muscle training (PIMT) using a threshold trainer for 30 min/day for 1 month before operation
Number of subjects: 30
Study 8549956 — intervention group
Group type: COMPARATOR
Intervention: Sham training (Control)
Number of subjects: 30
Study 2612249 — intervention group
Group type: EXPERIMENTAL
Intervention: Responsive maternal play technique; trained mothers
Number of subjects: 32
Study 2612249 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive mood induction
Number of subjects: 32
Study 2612249 — intervention group
Group type: COMPARATOR
Intervention: Negative mood induction
Number of subjects: 32
Study 12665 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose lorazepam
Number of subjects: 0
Study 12665 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose lorazepam
Number of subjects: 0
Study 12665 — intervention group
Group type: COMPARATOR
Intervention: Amylobarbitone
Number of subjects: 0
Study 30785704 — intervention group
Group type: EXPERIMENTAL
Intervention: Buccal graft
Number of subjects: 117
Study 30785704 — intervention group
Group type: EXPERIMENTAL
Intervention: Penile skin applied
Number of subjects: 117
Study 30785704 — intervention group
Group type: EXPERIMENTAL
Intervention: End-to-end anastomosis
Number of subjects: 117
Study 30785704 — intervention group
Group type: EXPERIMENTAL
Intervention: Neutrophil, lymphocyte counts and neutrophil/lymphocyte ratio
Number of subjects: 117
Study 28407184 — intervention group
Group type: EXPERIMENTAL
Intervention: Industrial tomato lines (CVR 1, CVR 3, CVR 4, CVR 5, CVR 21, CVR 22)
Number of subjects: 25
Study 28407184 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 25
Study 25867149 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulized 5% hypertonic saline
Number of subjects: 94
Study 25867149 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed 5% hypertonic saline with epinephrine
Number of subjects: 94
Study 25867149 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (placebo)
Number of subjects: 94
Study 22188047 — intervention group
Group type: EXPERIMENTAL
Intervention: Depression-focused interpersonal counseling (IPC)
Number of subjects: 103
Study 22188047 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 103
Study 20069390 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased serum cortisol levels
Number of subjects: 31
Study 20069390 — intervention group
Group type: EXPERIMENTAL
Intervention: Cortisol levels
Number of subjects: 31
Study 18767579 — intervention group
Group type: EXPERIMENTAL
Intervention: Cranial needling plus medication
Number of subjects: 43
Study 18767579 — intervention group
Group type: COMPARATOR
Intervention: Medication
Number of subjects: 43
Study 15930445 — intervention group
Group type: EXPERIMENTAL
Intervention: Safflower preload (SAFF)
Number of subjects: 25
Study 15930445 — intervention group
Group type: EXPERIMENTAL
Intervention: Walnut preload (WNT)
Number of subjects: 25
Study 15930445 — intervention group
Group type: EXPERIMENTAL
Intervention: Walnut oil preload (WOL)
Number of subjects: 25
Study 15930445 — intervention group
Group type: COMPARATOR
Intervention: Low-fat control (LFC)
Number of subjects: 25
Study 12880828 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine (12 microg/kg body weight)
Number of subjects: 0
Study 10233187 — intervention group
Group type: EXPERIMENTAL
Intervention: Tinidazole 500 mg (OCT)
Number of subjects: 120
Study 10233187 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronidazole 400 mg (OCM)
Number of subjects: 120
Study 10233187 — intervention group
Group type: COMPARATOR
Intervention: Both regimens (OCT and OCM)
Number of subjects: 120
Study 7759660 — intervention group
Group type: EXPERIMENTAL
Intervention: Metyrapone and hydrocortisone (30 mg daily hydrocortisone)
Number of subjects: 8
Study 7759660 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 1693740 — intervention group
Group type: EXPERIMENTAL
Intervention: Felodipine
Number of subjects: 134
Study 1693740 — intervention group
Group type: COMPARATOR
Intervention: Hydrochlorothiazide (HCT)
Number of subjects: 134
Study 84131 — intervention group
Group type: EXPERIMENTAL
Intervention: Levodopa
Number of subjects: 0
Study 84131 — intervention group
Group type: COMPARATOR
Intervention: Control (low-energy diet without levodopa)
Number of subjects: 0
Study 31774376 — intervention group
Group type: EXPERIMENTAL
Intervention: Natural foot-landing position
Number of subjects: 13
Study 31774376 — intervention group
Group type: EXPERIMENTAL
Intervention: Fore-foot landing position
Number of subjects: 13
Study 31774376 — intervention group
Group type: COMPARATOR
Intervention: Flat-foot landing position
Number of subjects: 13
Study 30377715 — intervention group
Group type: EXPERIMENTAL
Intervention: Tri-calcium phosphate (TCP) granule
Number of subjects: 54
Study 30377715 — intervention group
Group type: COMPARATOR
Intervention: Allogenous bone chip
Number of subjects: 54
Study 28862220 — intervention group
Group type: EXPERIMENTAL
Intervention: Prone position using belly board
Number of subjects: 22
Study 28862220 — intervention group
Group type: COMPARATOR
Intervention: Supine position
Number of subjects: 22
Study 25683704 — intervention group
Group type: EXPERIMENTAL
Intervention: Plant stanol esters (4 g)
Number of subjects: 14
Study 25683704 — intervention group
Group type: COMPARATOR
Intervention: Control (shake without plant stanol esters)
Number of subjects: 14
Study 23963128 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct supervision
Number of subjects: 53
Study 23963128 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediately available supervision
Number of subjects: 53
Study 23963128 — intervention group
Group type: EXPERIMENTAL
Intervention: Distant supervision
Number of subjects: 53
Study 23963128 — intervention group
Group type: COMPARATOR
Intervention: Unsupervised scenarios
Number of subjects: 53
Study 21748500 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic hypervolemic therapy
Number of subjects: 0
Study 21748500 — intervention group
Group type: EXPERIMENTAL
Intervention: Observational studies
Number of subjects: 0
Study 21748500 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperdynamic therapy
Number of subjects: 0
Study 19522983 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose squalene (27 g/day)
Number of subjects: 40
Study 19522983 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose squalene (13.5 g/day)
Number of subjects: 40
Study 19522983 — intervention group
Group type: EXPERIMENTAL
Intervention: Both doses of squalene
Number of subjects: 40
Study 17521741 — intervention group
Group type: EXPERIMENTAL
Intervention: Adrenaline (epinephrine)
Number of subjects: 0
Study 17521741 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 15373863 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery (ventilation tubes - VTs), n = 32
Number of subjects: 68
Study 15373863 — intervention group
Group type: COMPARATOR
Intervention: Control group, n = 36
Number of subjects: 68
Study 11710709 — intervention group
Group type: EXPERIMENTAL
Intervention: Ginger extract (EV.EXT 77), administered twice daily for 6 weeks
Number of subjects: 261
Study 11710709 — intervention group
Group type: EXPERIMENTAL
Intervention: Ginger extract (EV.EXT 77)
Number of subjects: 261
Study 11710709 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 261
Study 9172913 — intervention group
Group type: COMPARATOR
Intervention: AAS (Acetylsalicylic Acid)
Number of subjects: 0
Study 10150223 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-hospital beta-blocker treatment (intravenous injection of atenolol)
Number of subjects: 77
Study 10150223 — intervention group
Group type: COMPARATOR
Intervention: Pre-hospital placebo treatment
Number of subjects: 77
Study 29614993 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance training and protein supplementation (TRAINPRO)
Number of subjects: 37
Study 29614993 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance training (TRAIN)
Number of subjects: 37
Study 29614993 — intervention group
Group type: EXPERIMENTAL
Intervention: Protein supplementation (PRO)
Number of subjects: 37
Study 29614993 — intervention group
Group type: COMPARATOR
Intervention: Control stretching (STRETCH)
Number of subjects: 37
Study 27478133 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants resistant to decline in function (n=289)
Number of subjects: 594
Study 27478133 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants demonstrating resilience (n=137 of 239)
Number of subjects: 594
Study 27478133 — intervention group
Group type: EXPERIMENTAL
Intervention: High self-efficacy and social support
Number of subjects: 594
Study 24626120 — intervention group
Group type: EXPERIMENTAL
Intervention: Epinephrine (adrenaline)
Number of subjects: 0
Study 23652522 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-detection interval (30 of 40 intervals)
Number of subjects: 1902
Study 23652522 — intervention group
Group type: COMPARATOR
Intervention: Standard-detection interval (18 of 24 intervals)
Number of subjects: 1902
Study 23652522 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-detection interval
Number of subjects: 1902
Study 23652522 — intervention group
Group type: COMPARATOR
Intervention: Standard-detection interval
Number of subjects: 1902
Study 20006459 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient navigation services
Number of subjects: 35
Study 20006459 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 35
Study 18795673 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative radiotherapy (2500cGy/5 fractions)
Number of subjects: 150
Study 18795673 — intervention group
Group type: COMPARATOR
Intervention: Control group (no preoperative radiotherapy)
Number of subjects: 150
Study 16922907 — intervention group
Group type: EXPERIMENTAL
Intervention: Recruitment into the trial
Number of subjects: 113
Study 16922907 — intervention group
Group type: EXPERIMENTAL
Intervention: Reasons for non-entry
Number of subjects: 113
Study 16922907 — intervention group
Group type: EXPERIMENTAL
Intervention: Preference for surgery/surgeon
Number of subjects: 113
Study 16922907 — intervention group
Group type: EXPERIMENTAL
Intervention: Lack of time
Number of subjects: 113
Study 16922907 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospital accreditation issues
Number of subjects: 113
Study 16922907 — intervention group
Group type: EXPERIMENTAL
Intervention: Staffing/equipment issues
Number of subjects: 113
Study 16922907 — intervention group
Group type: EXPERIMENTAL
Intervention: Concern about doctor-patient relationship
Number of subjects: 113
Study 16922907 — intervention group
Group type: EXPERIMENTAL
Intervention: Anxiety caused to patients
Number of subjects: 113
Study 16922907 — intervention group
Group type: EXPERIMENTAL
Intervention: Availability of a data manager
Number of subjects: 113
Study 16922907 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased caseload
Number of subjects: 113
Study 12791627 — intervention group
Group type: EXPERIMENTAL
Intervention: 240 mL orange juice fortified with 1000 IU vitamin D(3) daily for 12 weeks
Number of subjects: 18
Study 12791627 — intervention group
Group type: COMPARATOR
Intervention: Control orange juice (not fortified)
Number of subjects: 18
Study 10815856 — intervention group
Group type: EXPERIMENTAL
Intervention: Flashlamp‐pumped pulsed dye laser (FPDL) therapy for superficial hemangiomas
Number of subjects: 165
Study 10815856 — intervention group
Group type: EXPERIMENTAL
Intervention: Flashlamp‐pumped pulsed dye laser (FPDL) therapy for mixed hemangiomas
Number of subjects: 165
Study 10815856 — intervention group
Group type: EXPERIMENTAL
Intervention: Flashlamp‐pumped pulsed dye laser (FPDL) therapy for superficial hemangiomas in involution phase
Number of subjects: 165
Study 8970899 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.2 g/day of oral calcium as carbonate
Number of subjects: 197
Study 8970899 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 197
Study 1460161 — intervention group
Group type: EXPERIMENTAL
Intervention: Preparatory videotape (11-min duration)
Number of subjects: 138
Study 1460161 — intervention group
Group type: COMPARATOR
Intervention: Control group (waiting period before appointment)
Number of subjects: 138
Study 1460161 — intervention group
Group type: EXPERIMENTAL
Intervention: Prepared group (viewed videotape)
Number of subjects: 138
Study 6698657 — intervention group
Group type: EXPERIMENTAL
Intervention: Acarbose (100 mg)
Number of subjects: 24
Study 6698657 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 30293544 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual Reality Simulation (VRS) training
Number of subjects: 0
Study 30293544 — intervention group
Group type: COMPARATOR
Intervention: Web-based Clinical Updates (CU)
Number of subjects: 0
Study 30286768 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation (50,000 IU every other week for 8 weeks)
Number of subjects: 40
Study 26780938 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate discontinuation group (IDG)
Number of subjects: 50
Study 26780938 — intervention group
Group type: COMPARATOR
Intervention: Tapered group (TG)
Number of subjects: 50
Study 24650219 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily 20 g lipid-based multi-micronutrient (MMN) supplement; additional 300 kcal/d for women with BMI <20 or low gestational weight gain
Number of subjects: 192
Study 24650219 — intervention group
Group type: COMPARATOR
Intervention: None (Control group)
Number of subjects: 192
Study 22436129 — intervention group
Group type: EXPERIMENTAL
Intervention: Febuxostat 80 mg
Number of subjects: 374
Study 22436129 — intervention group
Group type: EXPERIMENTAL
Intervention: Febuxostat 40 mg
Number of subjects: 374
Study 22436129 — intervention group
Group type: COMPARATOR
Intervention: Allopurinol 200/300 mg
Number of subjects: 374
Study 19460658 — intervention group
Group type: EXPERIMENTAL
Intervention: Family Healthware tool used directly after the baseline survey
Number of subjects: 3786
Study 19460658 — intervention group
Group type: COMPARATOR
Intervention: Control group used the Family Healthware tool after completing the follow-up survey
Number of subjects: 3786
Study 17495810 — intervention group
Group type: EXPERIMENTAL
Intervention: Demineralized bone transplant as osteoplastic material
Number of subjects: 0
Study 17495810 — intervention group
Group type: COMPARATOR
Intervention: Calcium hydroxyapatite preparations
Number of subjects: 0
Study 14962813 — intervention group
Group type: EXPERIMENTAL
Intervention: raloxifene (60 or 120 mg/day)
Number of subjects: 7705
Study 14962813 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 7705
Study 11591882 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycerol ingestion (1 g glycerol in 20 ml H2O x kg(‐1) body weight)
Number of subjects: 6
Study 11591882 — intervention group
Group type: COMPARATOR
Intervention: Control (20 ml H2O x kg(‐1) body weight)
Number of subjects: 6
Study 9870010 — intervention group
Group type: EXPERIMENTAL
Intervention: DDDR programming
Number of subjects: 407
Study 9870010 — intervention group
Group type: COMPARATOR
Intervention: VVIR programming
Number of subjects: 407
Study 7991650 — intervention group
Group type: EXPERIMENTAL
Intervention: Manipulation program with flexion and extension exercises (hand-heel rocks)
Number of subjects: 24
Study 7991650 — intervention group
Group type: COMPARATOR
Intervention: Extension program
Number of subjects: 24
Study 2928998 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled fenoterol (400, 600, and 800 micrograms)
Number of subjects: 8
Study 2928998 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled isoprenaline (400, 600, and 800 micrograms)
Number of subjects: 8
Study 2928998 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled salbutamol (400, 600, and 800 micrograms)
Number of subjects: 8
Study 2928998 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 30029716 — intervention group
Group type: EXPERIMENTAL
Intervention: Group counseling based on Bandura's self-efficacy theory (six 90-minute sessions over six weeks)
Number of subjects: 96
Study 30029716 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 96
Study 26316325 — intervention group
Group type: EXPERIMENTAL
Intervention: Epratuzumab (1,200 mg infusions at weeks 0 and 2 of repeating 12-week cycles) plus standard of care
Number of subjects: 203
Study 25867771 — intervention group
Group type: EXPERIMENTAL
Intervention: Vildagliptin 50 mg qd
Number of subjects: 162
Study 25867771 — intervention group
Group type: COMPARATOR
Intervention: NPH insulin qd
Number of subjects: 162
Study 23673304 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous Terbinafine (CTERB)
Number of subjects: 106
Study 23673304 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent Terbinafine (TOT)
Number of subjects: 106
Study 23673304 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsed Itraconazole (III)
Number of subjects: 106
Study 23673304 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined therapy (COMBO)
Number of subjects: 106
Study 20608826 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment of depression in patients with heart disease; specific intervention details not available.
Number of subjects: 0
Study 20608826 — intervention group
Group type: EXPERIMENTAL
Intervention: Recognition and treatment of depression; specific intervention details not available.
Number of subjects: 0
Study 18656572 — intervention group
Group type: EXPERIMENTAL
Intervention: Hispanic breast cancer survivors
Number of subjects: 330
Study 18656572 — intervention group
Group type: COMPARATOR
Intervention: Non-Hispanic white breast cancer survivors
Number of subjects: 330
Study 16204787 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled corticosteroids (ICS)
Number of subjects: 0
Study 16204787 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC)
Number of subjects: 0
Study 12598069 — intervention group
Group type: EXPERIMENTAL
Intervention: Active biventricular pacing
Number of subjects: 30
Study 10521635 — intervention group
Group type: EXPERIMENTAL
Intervention: Lateral glide treatment technique
Number of subjects: 8
Study 8904624 — intervention group
Group type: EXPERIMENTAL
Intervention: Miglitol
Number of subjects: 16